15th May , 2018



The Secretary,
Bombay Stock Exchange Limited
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai – 400 001.

BSE Scrip Code No.524280

The Secretary,
The National Stock Exchange of India
Limited, Exchange Plaza,
Bandra-Kurla Complex, Bandra (E),
Mumbai 400 051

NSE Symbol: KOPRAN

Re: Purchase of API Facility by Kopran Research Laboratories Limited, (Subsidiary Company)

Dear Sir,

Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, We hereby disclose that the Kopran Research Laboratories Limited, a wholly owned subsidiary of the Company has purchased API facility at Panoli, Gujarat as per the brief details given below

Name of the target Unit	Maxheal Pharmaceuticals (India) Limited, API facility at Panoli Gujarat on Slump Sale basis
Whether the acquisition would fall within related party transaction(s)	No
Whether the promoter/ promoter group / group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof	None
Industry to which the unit being acquired belongs	Pharmaceuticals







Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target Unit, if its business is outside the main line of business of the listed entity)	Expansion in existing line of Business
Brief details of any governmental or regulatory approvals required for the acquisition	None
Indicative time period for completion of the acquisition	One month
Nature of consideration - whether cash consideration or share swap and details of the same	Cash
Cost of acquisition	Enterprise value of the Unit 12.95 Crores
Brief background about the Unit acquired	The acquired Unit will be suitably upgraded and expanded. The expansion of the Unit is expected to be completed by December, 2018 to launch new line of products.

Regards,

For Kopran Limited

Sunit Sodhani

Company Secretary & Compliance Officer

